BRAF and melanoma: In contrast to dabrafenib, another BRAF inhibitor vemurafenib, which also suppresses proliferation of BRAF-mutated melanoma cells, does not suppress RIP3 activity, indicating that these kinase inhibitors act similarly, but their effect on cancer cells may differ depending on cellular context.